$JNJ

$JNJ JOHNSON & JOHNSON: LEERINK PARTNERS CUTS TARGET PRICE TO $272 FROM $276…

$JNJ - Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026…

$JNJ - Johnson & Johnson reports Q3 2026 results, raises 2026 guidance…

$JNJ - New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups…

$JNJ - TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease…

$JNJ - New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with p…

$JNJ Johnson & Johnson: Phase 3 ICONIC-TOTAL Two-Year ICOTYDE Data Show High Complete Clearance Rates at Difficult Psoriasis Sites ? • At Week 112, 60…

$JNJ - Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affi…

$JNJ - Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu)…

$JNJ - Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stif…

$JNJ J&J - FIVE-YEAR OVERALL SURVIVAL RATE 69.2%, MEDIAN PROGRESSION-FREE SURVIVAL 60.5 MONTHS…

$JNJ - New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fi…

$JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-re…

$JNJ - Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026…

$JNJ - Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit…